- Home
- OMGA vs BIVI Comparison
OMGA vs BIVI Comparison
Compare OMGA & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMGA
- BIVI
- Stock Information
- Founded
- OMGA 2017
- BIVI 2013
- Country
- OMGA United States
- BIVI United States
- Employees
- OMGA N/A
- BIVI N/A
- Industry
- OMGA Biotechnology: Pharmaceutical Preparations
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- OMGA Health Care
- BIVI Health Care
- Exchange
- OMGA Nasdaq
- BIVI Nasdaq
- Market Cap
- OMGA 27.1M
- BIVI 49.8M
- IPO Year
- OMGA 2021
- BIVI N/A
- Fundamental
- Price
- OMGA $0.14
- BIVI $1.70
- Analyst Decision
- OMGA Strong Buy
- BIVI Strong Buy
- Analyst Count
- OMGA 5
- BIVI 1
- Target Price
- OMGA $9.20
- BIVI $30.00
- AVG Volume (30 Days)
- OMGA 1.2M
- BIVI 961.5K
- Earning Date
- OMGA 03-27-2025
- BIVI 02-11-2025
- Dividend Yield
- OMGA N/A
- BIVI N/A
- EPS Growth
- OMGA N/A
- BIVI N/A
- EPS
- OMGA N/A
- BIVI N/A
- Revenue
- OMGA $8,095,000.00
- BIVI N/A
- Revenue This Year
- OMGA $181.38
- BIVI N/A
- Revenue Next Year
- OMGA N/A
- BIVI N/A
- P/E Ratio
- OMGA N/A
- BIVI N/A
- Revenue Growth
- OMGA 185.04
- BIVI N/A
- 52 Week Low
- OMGA $0.14
- BIVI $1.04
- 52 Week High
- OMGA $4.46
- BIVI $33.10
- Technical
- Relative Strength Index (RSI)
- OMGA 19.88
- BIVI 30.68
- Support Level
- OMGA $0.44
- BIVI $1.63
- Resistance Level
- OMGA $0.54
- BIVI $2.29
- Average True Range (ATR)
- OMGA 0.09
- BIVI 0.15
- MACD
- OMGA -0.02
- BIVI -0.03
- Stochastic Oscillator
- OMGA 2.09
- BIVI 14.58
About OMGA Omega Therapeutics Inc.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.